Background {#Sec1}
==========

Economic evaluations are increasingly used to assist in decision making of interventions. Often for a specific decision problem different economic evaluations are conducted. The results of these studies may differ substantially between studies: from interventions being dominated to being dominant. Therefore, it is necessary that systematic reviews are performed to summarize the results of the individual economic evaluations. Besides summarizing the study characteristics and results it would be interesting to explain statistically the variability in the incremental costs and incremental effects and thus the conclusions. Differences can exist due to differences in values used for input parameters, perspective, time horizon and other factors. Some differences could easily be explained by the values that were used for the input parameters, since for some input parameters a linear relationship with the outcomes exists. For example, an increase in initial intervention costs will lead to an increase in the incremental costs, ceteris paribus. Often these variations are explained by sensitivity analyses of individual studies. Other associations with input parameters that do not have a linear association with the outcome (e.g., probabilities leading to changes in costs and effects) or study characteristics (e.g., funding) could be identified using meta-regression analyses in addition to conventional systematic review methods. Meta-regression analyses are currently used to combine the results of clinical trials and to investigate the effect of methodological diversity of the studies on the results \[[@CR1]\]. To explain the variability in the incremental costs and incremental effects of cost-effectiveness analysis (CEA) it could be useful to apply these meta-regression analyses in systematic reviews of economic evaluations.

The aim of this study is to explore the usefulness of meta-regression analyses in systematically explaining the variability in the results compared with conventional review methods and sensitivity analyses of individual studies. Meta-regression analyses may be useful if they provide more information, in terms of associations with the outcomes, than conventional systematic reviews and sensitivity analyses. Many economic evaluations have estimated the cost-effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS) for the treatment of patients with coronary artery disease. The results between the studies vary considerably, which makes this decision problem a good case study to explore if meta-regression analyses are of added value. Systematic reviews \[[@CR2]--[@CR4]\] on the cost-effectiveness of DES versus BMS have been performed but did not explore statistically the causes of the variability in incremental costs and incremental effects between the studies. Associations with the incremental outcomes (costs, quality-adjusted life years and repeat revascularizations avoided) will be identified in this study. Besides the 'known' factors (e.g., age, type of lesion, price of stents, relative risk repeat revascularisations avoided) explaining the cost-effectiveness of DES versus BMS we will identify associations that could only be identified at a meta-level such as the quality of the studies and funding.

Methods {#Sec2}
=======

Inclusion and exclusion criteria {#Sec3}
--------------------------------

A systematic literature search was performed to identify all English-language (online or print) publications (at any time before January 2012) of CEAs using decision analytic models to compare the costs and consequences of DES (sirolimus-eluting stent (SES), paclitaxel-eluting stent (PES), everolimus or zotarolimus-eluting stent (ZES)) versus BMS for patients who require a stent implantation due to an atherosclerotic lesion of the coronary artery. The effectiveness of the studies had to be expressed in quality adjusted life years (QALY) or in disease specific measures such as repeat revascularizations avoided, TLR (target lesion revascularization) and TVR (target vessel revascularization). Furthermore, studies were only included if they reported results in enough detail to enable separation of incremental costs from incremental effects. There was no restriction on the perspective used in the economic evaluation. Reviews, editorials and abstracts were not included in the review.

Studies were identified using electronic databases (PubMed, EMbase, NHS EED, Cochrane Library and INAHTA) and by scanning reference lists of eligible articles. The full search strategies for EMbase and PubMed are presented in Additional file [1](#MOESM1){ref-type="media"}. To ensure that all relevant publications were identified in the CRD (NHS EED and HTA) and Cochrane Library databases we limited the search terms to "stent" and "stents". These terms were searched in "any field" for CRD and in "title, abstract, keywords" for Cochrane Library. We also included the relevant publications found in the reviews by Ligthart et al. \[[@CR4]\], Hill et al. \[[@CR2]\], and Neyt et al. \[[@CR3]\].

Data extraction {#Sec4}
---------------

One reviewer (LB) screened the titles and abstracts identified through the searches. The full text evaluation was performed by two reviewers (LB & FW) and discrepancies were discussed and resolved by consensus or by consulting a third reviewer (WR). Various parameters (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}) were extracted from the relevant publications by one reviewer (LB). The parameters chosen in the regression analyses were the most likely general study characteristics (e.g., population, time horizon, funding) that are reported in conventional systematic reviews. In addition, we added the most important input parameters (e.g., cost of procedure, relative risk of repeat revascularization, probability of repeat revascularization, utilities) that are used in the model to estimate the cost-effectiveness. These key parameters are often varied in deterministic sensitivity analyses. Costs were converted to Euros \[[@CR5]\] and corrected for inflation if necessary \[[@CR6]\] to present the costs as 2012 Euros. Furthermore, we wanted to see if modelling assumptions (e.g., oculo-stenotic effect) were of influence on the incremental outcomes. All assumptions reported in the studies were monitored. Lastly, two reviewers (LB & FW) independently assessed the quality of the models using the Philips et al. checklist \[[@CR7]\] for the assessment of model-based economic analyses. The Philips checklist is a framework based on existing guidelines on the use of decision analytic modelling in health technology assessments. The checklist is structured in three themes: a) structure, which focusses on the scope and mathematical structure; b) data, which examines data identification and uncertainty methods; and c) consistency, which assesses the overall quality of the model based on the publication. Both overall study quality and the quality per theme were given a score from 0-100 %, which was calculated by dividing the sum of the questions answered positively by the total number of relevant questions. Since some questions were not relevant for all studies (e.g., questions concerning quality-of-life values) the denominator could differ between studies.Table 1Description economic evaluationsStudyYearCountry\# AnalysesHorizon (months)ModelFunding^b^SubgroupsComparisonPrice per stent (2012 €)Price difference DES vs BMS (2012 €)\# Stents per procedureQuality (%)^a^Ekman et al. \[[@CR15]\]2004Sweden6612,24DTYesHigh risk, diabetes, type of lesion, type of vesselBMS vsNS1.1-1.841 PESNS693-1271Hill et al. \[[@CR22]\]2004UK3612-60STMNoHigh risk, \# vesselsBMS vs6791.3,2.477 DES1607929Tarricone et al. \[[@CR19]\]2004Italy1012DTYes\# vessels, diabetes, type of lesion, type of vesselBMS vsNS1.2 -- 2.646 SESNS0Bowen et al. \[[@CR21]\]2005Canada5012DTNoPost MI, diabetes, type of lesionBMS vs5311.23--2.2661 DES16811150Mittmann et al. \[[@CR13]\]2005Canada812DTNSBMS vs5221.550 SES20621540 PES20621540Shrive et al. \[[@CR17]\]2005Canada11LTSTMYesDiabetes, ageBMS vs4301.05--1.7556 SES1246-3114816-2685Mahieu et al. \[[@CR12]\]2006Belgium3112DTNSDiabetes, type of lesion, type of vesselBMS vsNS132 SESNS731-1306 PESNS731-1306Hill et al. \[[@CR2]\]2007UK17212STMNoHigh risk, electiveBMS vs4851-280 SES1700-17741215-1289 PES1621-16961136-1211Kuukasjarvi et al. \[[@CR23]\]2007Finland224DTNoBMS vsNSNS33 DESNSNSNeyt et al. \[[@CR8]\]2007Belgium5912DTNSDiabetes, \# vessels, type of lesionBMS vs553-11061.09--1.9772 DES553-16590-1106Polanczyk et al. \[[@CR18]\]2007Brazil412, LTSTMYesBMS vs831-13901.256 SES31691779, 2337Bischof et al. \[[@CR14]\]2009USA436STMNoBMS vsNSNSNS76 SESNS PESNSGoeree et al.\[[@CR24]\]2009Canada4524DTNoDiabetes, type of lesion, type of vesselBMS vs4701.1--2.3752 DES1486391-1016Ferreira et al. \[[@CR16]\]2010Brazil126DTNoBMS vs1883NS36 PES52723390Jahn et al. \[[@CR10], [@CR11]\]2010Austria684DESNoDiabetes, type of lesionBMS vsNS1.2447 DESNSNSRemak et al. \[[@CR20]\]2010UK348STMYesBMS vs4331.1162 ZES11757421.12-1.4^a^ Philips checklist 2006: scale 0-100 %^b^ Yes: manufacturer; No: funded by government or not funded*DES* discrete event simulation, *DT* decision tree, *LT* life time, *vs* versus, *MI* myocardial infarction, *NS* not stated, *STM* state-transition model, *\# vessels* number of vessels treated

Analysis {#Sec5}
--------

The influence of modelling methods, the choice of parameters and the quality of the models on the main outcomes (incremental costs, incremental QALYs and absolute risk reduction repeat revascularizations) were analysed both quantitatively and qualitatively. Associations between parameters and the outcomes were assessed by identifying outliers found on cost-effectiveness planes. Furthermore, several bivariate linear regressions were estimated to confirm the associations and also to measure the influence of other parameters on the outcomes. Including associations that could be predicted beforehand (e.g., type of lesion, price stent) are included in the regression analyses since it could be seen as a validation check if the analyses also show these associations. Multivariate analyses with all of the parameters that were significant in the bivariate analyses could not be performed due to a high frequency of missing values caused by incomplete reporting.

We included every subgroup or sensitivity analysis found in a study as long as incremental costs or incremental effectiveness were provided or could be calculated. As a result, our meta-regression analyses were based on many more observations than the number of studies that were included. Since Hill et al. \[[@CR2]\] provided more than 30 % of the observations used in our study; we incorporated study ID as a random effect in the regression models. Some studies reported both incremental effects and incremental QALYs for a specific analysis. Since the incremental costs associated with both outcomes is the same we only included one of the two analyses for the regression analyses on the incremental costs to avoid double counting. Data management and all statistical analyses were performed with SPSS 19.0 (SPSS Inc., Chicago, IL, USA). The level of measurement was ordinal or ratio, depending on the covariate. The model assumptions and study characteristics (e.g., funding) were measured at an ordinal scale. Input parameters such as the probability of repeat revascularization were measured at a ratio scale. Conclusions about statistical significant were based on an alpha level of 5 %.

Results {#Sec6}
=======

Figure [1](#Fig1){ref-type="fig"} presents the process of identifying relevant publications in line with PRISMA guidelines (Additional file [2](#MOESM2){ref-type="media"}). Of the 1957 potentially relevant publications, 1872 were excluded based on title, abstract and keywords. Full-text evaluation was performed for 85 articles leading to 18 relevant studies. Reasons to exclude studies after a full text assessment were: lack of a model (*n* = 24), no original CEA (*n* = 22), language other than English (*n* = 8), no relevant outcome (*n* = 6), comparator not BMS (*n* = 4), and results were not presented at a disaggregated level (*n* = 3). In one case, we found that a full report \[[@CR8]\] and a paper \[[@CR9]\] reported results from the same analyses; data was therefore extracted from the full report. In another case, we found two papers with the same content and results and considered them as one paper \[[@CR10], [@CR11]\].Fig. 1Flow of studies through the review process. PES: paclitaxel eluting stent; SES: sirolimus eluting stent; ZES: zotarolimus eluting stent; DES: drug eluting stent

The 16 eligible studies were divided into five groups based on the type of DES that was evaluated and accounted for 498 separate analyses (Table [1](#Tab1){ref-type="table"}). Four studies calculated the incremental cost-effectiveness ratio (ICER) for both PES and SES \[[@CR2], [@CR12]--[@CR14]\], two studies \[[@CR15], [@CR16]\] focused on PES, three studies focused only on SES \[[@CR17]--[@CR19]\], and one study used ZES as the intervention \[[@CR20]\]. The remaining six publications \[[@CR8], [@CR10], [@CR11], [@CR21]--[@CR24]\] did not specifically identify the type of eluting drug under evaluation and calculated an ICER for a DES in general,

Descriptive characteristics {#Sec7}
---------------------------

In most analyses, DES was more expensive (88 % of analyses) and more effective in both QALYs and repeat revascularizations avoided (99 % of analyses) than BMS. Most of the 16 studies \[[@CR2], [@CR8], [@CR10], [@CR11], [@CR14], [@CR16], [@CR21], [@CR23]\] concluded that DES is not cost-effective for all subgroups since the incremental QALYs did not offset the incremental costs. However, many concluded that DES was more cost-effective in high-risk patients. The ICER varied considerably between and within studies: from DES being dominated by BMS \[[@CR14], [@CR21]\] to DES being dominant in specific analyses \[[@CR2], [@CR8], [@CR10], [@CR11], [@CR15], [@CR19], [@CR22]\]. Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} present the variability of the incremental costs and effects of the studies using repeat revascularizations avoided or QALYs as an outcome measure, respectively. The mean values of input parameters stratified by the type of study outcome are presented in Table [2](#Tab2){ref-type="table"}.Fig. 2Cost-effectiveness plane, repeat revascularizations avoidedFig. 3Cost-effectiveness plane, quality-adjusted life years gained. \* The lines present the willingness to pay thresholds of 20,000 per QALY gained and 30,000 per QALY gained. The threshold in the Netherlands is between 20,000 - 80,000 per QALY gained \[[@CR32]\]Table 2Averages economic evaluations (univariate analyses)Total (CEAs & CUAs) (*N* = 16)CEAs (*N* = 9)CUAs (*N* = 11)Average ± SDAverage ± SDAverage ± SD*Incremental outcomes* Incremental costs€982 ± €894 Incremental QALYs0.0042 ± 0.008 Incremental repeat revascularization avoided0.0958 ± 0.0521*Input parameters* Number of stents per procedure1.503 ± 0.3671.382 ± 0.3551.540 ± 0.364 Price of DES stent€ 1,654 ± € 390€ 1,912 ± € 672€ 1,614 ± € 307 Price of BMS stent€ 555 ± € 166€ 670 ± € 307€ 534 ± € 114 Price difference between stents€ 1,085 ± € 337€ 1,189 ± € 336€ 1,056 ± € 331 Price of DES procedure (incl. stents)€ 6,328 ± € 2,509€ 7,811 ± € 1,475€ 5,998 ± € 2,573 Price of BMS procedure (incl. stents)€ 4,442 ± € 2,195€ 6,259 ± € 1,536€ 4,160 ± € 2,138 Cost difference between the procedures€ 1,787 ± € 686€ 1,551 ± € 805€ 1,840 ± € 647 Probability restenosis BMS0.142 ± 0.0760.148 ± 0.0550.140 ± 0.081 Probability restenosis DES0.064 ± 0.0380.056 ± 0.0270.068 ± 0.041 Relative risk reduction DES vs. BMS0.484 ± 0.2040.578 ± 0.2140.449 ± 0.189*Quality (0-100 %)\** Total59.5 ± 15.4 Structure62.5 ± 16.1 Data56.7 ± 21.6 Consistency55.1 ± 20.8\* *N* = 16 studies*CEA* cost-effectiveness analysis, *CUA* cost-utility analysis

We also assessed the quality of the models of all studies using the Philips et al. \[[@CR7]\] checklist. Studies appeared to score higher on the theme structure (63 % ± 16 %) than on the other two themes, data (57 % ± 22 %) and consistency (55 % ± 21 %). The average overall quality of the models was moderate (59 % ± 15 % of a maximum possible score of 100 %).

Outcome repeat revascularizations avoided {#Sec8}
-----------------------------------------

Based on 124 separate analyses (9 studies), the number of repeat revascularizations avoided (the absolute risk reduction in repeat revascularizations) with DES also varied considerably (Fig. [2](#Fig2){ref-type="fig"}) between and within studies (range: −0.0001, 0.19), which resulted in variation in the ICERs. The overall conclusions of most of the studies corresponded with the 124 separate analyses (Table [3](#Tab3){ref-type="table"}). The regression analyses showed that the relative risk reduction of repeat revascularizations and the initial probabilities of restenosis were positively associated with repeat revascularizations avoided. Furthermore, a more complex vessel or lesion was associated with higher relative risk reduction and initial risk of restenosis after a percutaneous coronary intervention with BMS. Consequently, this leads to an increase in repeat revascularizations avoided and DES becomes more effective. Furthermore, the number of stents was also positively and significantly associated with repeat revascularizations avoided, probably because it is a proxy for subgroups who have a higher risk of developing restenosis due to diabetes, lesions and vessels characteristics. These factors could have been predicted beforehand since subgroup analyses and sensitivity analyses of the individual studies show the same conclusions.Table 3Associations between incremental revascularizations and covariates -- DES vs BMS^a^Bivariate∆ Repeat revascularization ^d^CovariatesβNse120*Population* Age70  Age \>75NA0NA  Age 65-75−0.01880.05  Age \< 65ref62 Complex lesion (yes vs. no)0.029\*560.007 Complex vessel (yes vs. no)0.042\*270.012 Multi vessel disease (yes vs. no)0.019\*120.007 Diabetes (yes vs. no)0.02\*640.007 Post MI (yes vs. no)0.007250.011 Elective (yes vs. no)NA0NA High risk (yes vs. no)NA0NA*Intervention* Type DES120  Sirolimus eluting stent0.102\*210.014  Paclitaxel eluting stent0.063\*560.014  Zotarolimus eluting stentNA0NA  Drug eluting stent in generalref43*Study characteristics* Country120  Canada−0.099420.056  Sweden−0.036270.068  Brazil−0.0850.072  Finland−0.0410.072  Belgium−0.07390.059  Italyref10 Study year0.011200.008 Horizon \>1 year (yes vs. no)−0.0061200.021 Horizon (months) ^b^\<0.001 Type of study (CUA vs. CEA)NANANA Model120  Markov modelNA0NA  Discrete event simulation modelNA0NA  Decision treeNA120NA Perspective120  Health care provider perspective0.00460.017  Health care sector perspective0.04310.05  Non-public perspectiveNA0NA  Health care payer perspectiveref83 Funding73  No0.034270.045  Yes46   Both Industry and No industryNA0NA   Industry0.102\*370.046  No industryref9 Discounting (yes vs. no)^c^−0.084\*110.026*Input parameters* Number of stents used during the procedure0.033\*1110.01 Price difference between stentsNANANA Price of BMS stentNANANA Price of DES stentNANANA Costs of BMS procedure (incl. stents)NANANA Costs of DES procedure (incl. stents)NANANA Difference in procedure costsNANANA **Probability of restenosis BMS0.521\***1120.041 Probability of restenosis DES0.436\*1120.127 **Relative risk reduction repeat revascularization0.132\***1120.018 Disutility of undergoing a CABGNANANA Disutility of undergoing a PCINANANA Disutility of experiencing a MINANANA Disutility for a patient with angina symptomsNANANA Quality of life of a patient with angina symptomsNANANA Quality of life of a patient after revascularization (recovered)NANANA Quality of life of a patient suffering from restenosisNANANA*Assumptions* Difference in clopidogrel (medication) usage (yes vs. no)0.001450.015 Wait time for revascularization included (yes vs. no)−0.051770.048 Repeat revascularization is based on angiographic follow-up data (yes vs. no)0.082\*820.01 DES and BMS are not mixed up during a procedure−0.0611200.047 Repeat interventions that occur during time horizon are the result of restenosisNA120NA There do not exist differences in mortality, thrombosis or MI between DES and BMS0.0391200.039 The type of repeat revascularization is the same for the DES and BMS treatment groups−0.0711200.044 There does not exist a difference in survival between DES and BMS0.0151200.033 There does not exist a difference in thrombosis between DES and BMS0.0391200.039 There does not exist a difference in MI between DES and BMS0.0461200.031*Quality of studies (Philips* et al. *2006)* \[[@CR7]\] Structure (%)−0.1451200.099 Data (%)−0.167\*1200.066 Consistency (%)−0.1531200.081 Total (%)−0.250\*1200.087^a^ Corrected for study; ^b^Shrive et al. & Remak et al. \[[@CR17], [@CR20]\] not included (lifetime horizon); ^c^ only studies with a time horizon longer than 1 year included; ^d^incremental repeat revascularization avoided; \**p* value \< 0.05*CEA* cost effectiveness analysis, *CUA* cost utility analysis, *DES* drug eluting stent, *MI* myocardial infarction, *NA* not applicable, *BMS* bare metal stent, *CABG* coronary artery bypass graft, *DES* drug eluting stent, *MI* myocardial infarction, *NA* not applicable, *PCI* percutaneous coronary intervention

Besides these factors that could be predicted beforehand, with the meta-regression analyses we were able to find a negative association between overall quality of a model and repeat revascularizations avoided. Furthermore, the theme data was also negatively associated with this incremental outcome. Consequently, models with a higher quality led to less favourable results for DES.

Outcome of incremental QALYs {#Sec9}
----------------------------

Figure [3](#Fig3){ref-type="fig"} presents the incremental QALYs and incremental costs for 384 separate cost-effectiveness analyses (11 studies). This Figure shows that Shrive et al. \[[@CR17]\] and Remak et al. \[[@CR20]\] clearly found a larger incremental QALY gain than the other studies.

Again, the meta-regression analyses found associations with incremental QALYs that were expected (Table [4](#Tab4){ref-type="table"}). Relative risk reduction of repeat revascularizations and the initial probability of restenosis after BMS were associated with a greater QALY gain, as seen in individual sensitivity analyses \[[@CR2], [@CR14], [@CR15], [@CR21], [@CR22], [@CR24]\]. Furthermore, analyses showed that non-elective patients, patients with a high risk of a repeat revascularization, patients with complex vessels or lesions or older patients will benefit more from DES, something that was also recognised in the individual studies \[[@CR2], [@CR12], [@CR17], [@CR21], [@CR24]\]. In addition, we found a significant positive association between time horizon (continuous) and incremental QALYs. This was also found by Hill et al. \[[@CR22]\] and Ekman et al. \[[@CR15]\] who varied the time horizon in the sensitivity analyses.Table 4Associations between incremental QALYs and covariates -- DES vs BMS^a^Bivariate∆ QALYsCovariatesβNse384*Population* Age190  Age \>750.029\*10.002  Age 65-750.015\*520.002  Age \< 65ref137 Complex lesion (yes vs. no)0.001\*123\<0.001 Complex vessel (yes vs. no)0.001\*51\<0.001 Multi vessel disease (yes vs. no)0.00190\<0.001 Diabetes (yes vs. no)\<0.001135\<0.001 Post MI (yes vs. no)\<0.001250.001 Elective (yes vs. no)−0.001\*208\<0.001 High risk (yes vs. no)0.004\*1270.001*Intervention* Type DES384  Sirolimus eluting stent0.01750.009  Paclitaxel eluting stent0.0111510.009  Zotarolimus eluting stent0.02530.015  Drug eluting stent in generalref155*Study characteristics* Country384  United Kingdom0.0112110.015  United States0.00140.019  Canada0.016720.015  Sweden0.002390.019  Austria0.00160.019  Finland0.00510.019  Belgium51 Study year0.0013840.002 Horizon \>1 year (yes vs. no)0.0023840.001 Horizon (months) ^b^\<0.001\*373\<0.001 Type of study (CUA vs. CEA)NANANA Model384  Markov model0.0142260.008  Discrete event simulation model0.00160.014  Decision treeref152 Perspective384  Health care provider perspective0.00670.012  Health care sector perspectiveNA0NA  Non-public perspectiveNA0NA  Health care payer perspectiveref377 Funding333  No−0.00130  Yes303   Both Industry and No industry0.043\*110.008   Industry0.012420.006   No industryref250Discounting (yes vs. no)^c^0.015900.013*Input parameters* Number of stents used during the procedure0.0013790 Price difference between stentsNANANA Price of BMS stentNANANA Price of DES stentNANANA Costs of BMS procedure (incl. stents)NANANA Costs of DES procedure (incl. stents)NANANA Difference in procedure costsNANANA Probability of restenosis BMS0.024\*3660.001 Probability of restenosis DES0.0052820.004 Relative risk reduction repeat revascularization0.007\*3000.001 Disutility of undergoing a CABG−0.747\*2540.163 Disutility of undergoing a PCI−0.1072540.433 Disutility of experiencing a MI−0.021400.097 Disutility for a patient with angina symptoms−0.012780.013 Quality of life of a patient with angina symptoms−0.231\*3380.04 Quality of life of a patient after revascularization (recovered)−0.24\*3800.024 Quality of life of a patient suffering from restenosis−0.254\*1440.031*Assumptions* Difference in clopidogrel (medication) usage (yes vs. no)\<0.0012700.001 Wait time for revascularization included (yes vs. no)−0.012\*3360.006 Repeat revascularization is based on angiographic follow-up data (yes vs. no)0.013\*3290.006 DES and BMS are not mixed up during a procedure0.0023840.01 Repeat interventions that occur during time horizon are the result of restenosis0.02\*3840.01 There do not exist differences in mortality, thrombosis or MI between DES and BMS−0.0033840.016 The type of repeat revascularization is the same for the DES and BMS treatment groups−0.0083840.016 There does not exist a difference in survival between DES and BMS0.0013840.002 There does not exist a difference in thrombosis between DES and BMS−0.0033840.016 There does not exist a difference in MI between DES and BMS−0.0063840.01*Quality of studies (Philips* et al. *2006)* \[[@CR7]\] Structure (%)−0.0063840.033 Data (%)0.0063840.024 Consistency (%)−0.0183840.02 Total (%)\<0.0013840.032^a^ Corrected for study; ^b^Shrive et al. & Remak et al. \[[@CR17], [@CR20]\] not included (lifetime horizon); ^c^ only studies with a time horizon longer than 1 year included; \* *p* value \< 0.05*CEA* cost effectiveness analysis, *CUA* cost utility analysis, *DES* drug eluting stent, *MI* myocardial infarction, *NA* not applicable, *BMS* bare metal stent, *CABG* coronary artery bypass graft, *DES* drug eluting stent, *MI* myocardial infarction, *NA* not applicable, *PCI* percutaneous coronary intervention

Studies \[[@CR2], [@CR17]\] that have explicitly mentioned that they have assumed that the occurrence of repeat revascularizations within the time horizon is the result of restenosis and studies assuming that repeat revascularization rates are based on angiographic follow-up have estimated significantly higher incremental QALYs. Angiographic follow-up leads to inflated estimates of clinical effectiveness compared with clinical follow-up since not clinically significant restenosis results in "unnecessary" repeat revascularizations when angiographic follow-up is performed. Consequently, the difference in repeat revascularizations will be overestimated (oculo-stenotic effect) \[[@CR25]\]. Some studies use "real-world" \[[@CR8], [@CR10], [@CR11], [@CR21]\] follow-up data and consequently report lower estimates (visible in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}) than other studies such as, Remak et al. \[[@CR20]\] that used angiographic follow-up \[[@CR12], [@CR15], [@CR17], [@CR23]\]. This phenomenon is described earlier by Eisenberg et al. \[[@CR26]\], who concluded that cost-effectiveness studies using angiographic follow-up overestimate the cost-effectiveness of DES.

The meta-regression analyses showed that studies using real-world evidence compared with angiographic follow-up leads to a reduction in incremental QALY gain. The added value of meta-regression analyses is limited in explaining the variation in incremental QALYs, although it identified modelling assumptions that were significantly associated with incremental QALYs.

Outcome incremental costs {#Sec10}
-------------------------

Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} show that there was large variation in incremental costs (range: €-4070 to €3506). Regression analyses (Table [5](#Tab5){ref-type="table"}) confirmed associations (cost parameters and population characteristics) that were seen in the individual studies \[[@CR2], [@CR8], [@CR12], [@CR17], [@CR20], [@CR21], [@CR24]\]. The analyses showed that probability of restenosis after BMS, the reduction in restenosis risk by DES, the difference in stent price, and the number of stents used were important parameters influencing the incremental costs. Both input parameters varied considerably between the analyses: the difference in stent costs ranged from €0 \[[@CR8], [@CR19]\] to €2685 \[[@CR17]\] and the number of stents varied between 1 \[[@CR22]\] and 2.6 \[[@CR19]\] stents per procedure depending on the type of patient.Table 5Associations between incremental costs and covariates -- DES vs BMS^a^Bivariate∆ Costs (2012€)CovariatesβNse437*Population* Age190  Age \>753151901  Age 65-75−3152695  Age \< 65ref137 Complex lesion (yes vs. no)172\*13485 Complex vessel (yes vs. no)−562116 Multi vessel disease (yes vs. no)12298200 Diabetes (yes vs. no)−217\*15078 Post MI (yes vs. no)−882588 Elective (yes vs. no)346\*208109 High risk (yes vs. no)−291127193*Intervention* Type DES437  Sirolimus eluting stent551100636  Paclitaxel eluting stent379180636  Zotarolimus eluting stent−32431321  Drug eluting stent in generalref154*Study characteristics* Country437  United Kingdom2147\*211836  United States4425\*41050  Canada2922\*79808  Sweden1745391016  Brazil3444\*5932  Austria175261035  Finland205111174  Belgium169882879  Italyref10 Study year−190437137 Horizon \>1 year (yes vs. no)−479437277 Horizon (months) ^b^−32\*4146 Type of study (CUA vs. CEA)−194\*50786 Model437  Markov model613230611  Discrete event simulation model−43561219  Decision treeref201 Perspective437  Health care provider perspective26614363  Health care sector perspective−1332311151  Non-public perspective−10572670  Health care payer perspectiveref390 Funding347  No1480\*31634  Yes316   Both Industry and No industry1246111041   Industry−62156663   No industryref249Discounting (yes vs. no)^c^107191713*Input parameters* Number of stents used during the procedure708\*42483 Price difference between stents1.264\*4180.13 Price of BMS stent0.503\*3200.354 Price of DES stent1.001\*3120.152 Costs of BMS procedure (incl. stents)0.339\*2780.092 Costs of DES procedure (incl. stents)0.412\*2780.053 Difference in procedure costs0.799\*2780.075 Probability of restenosis BMS**−3072\***407322 Probability of restenosis DES−1907\*323899 Relative risk reduction repeat revascularization**−1676\***341250 Disutility of undergoing a CABGNANANA Disutility of undergoing a PCINANANA Disutility of experiencing a MINANANA Disutility for a patient with angina symptomsNANANA Quality of life of a patient with angina symptomsNANANA Quality of life of a patient after revascularization (recovered)NANANA Quality of life of a patient suffering from restenosisNANANA*Assumptions* Difference in clopidogrel (medication) usage (yes vs. no)181279216 Wait time for revascularization included (yes vs. no)−733347486 Repeat revascularization is based on angiographic follow-up data (yes vs. no)−593372492 DES and BMS are not mixed up during a procedure−542437741 Repeat interventions that occur during time horizon are the result of restenosis855437841 There do not exist differences in mortality, thrombosis or MI between DES and BMS−980437878 The type of repeat revascularization is the same for the DES and BMS treatment groups5014371187 There does not exist a difference in survival between DES and BMS−238437426 There does not exist a difference in thrombosis between DES and BMS−589437754 There does not exist a difference in MI between DES and BMS−595437665*Quality of studies (Philips* et al. *2006)* \[[@CR7]\] Structure (%)21544371819 Data (%)16704371318 Consistency (%)7184371463 Total (%)27614371804^a^ Corrected for study; ^b^Shrive et al. & Remak et al. \[[@CR17], [@CR20]\] not included (lifetime horizon); ^c^ only studies with a time horizon longer than 1 year included; \* *p* value \< 0.05*CEA* cost effectiveness analysis, *CUA* cost utility analysis, *DES* drug eluting stent, *MI* myocardial infarction, *NA* not applicable, *BMS* bare metal stent, *CABG* coronary artery bypass graft, *DES* drug eluting stent, *MI* myocardial infarction, *NA* not applicable, *PCI* percutaneous coronary intervention

On a meta-level we were able to conclude that funding and the type of cost-effectiveness analysis was associated with incremental costs. Funding was provided by the stent manufacturer in five \[[@CR15], [@CR17]--[@CR20]\] of the 16 studies and three of them \[[@CR15], [@CR17], [@CR20]\] concluded that DES was cost-effective compared with BMS. Of the studies that were not *funded by a manufacturer* (*N* = 8) only one \[[@CR10], [@CR11]\] of them concluded that DES could be cost-effective. Studies that were not funded estimated on average higher incremental costs than studies that were (*p* \< 0.05). Furthermore, some associations with incremental costs are recognised from scenario analyses performed by studies. The directions of the following associations are confirmed by the regression analysis but not significant. According to Jahn et al. \[[@CR10], [@CR11]\] it is important to incorporate wait time into the model since it leads to a decrease (−734, 95 % CI:-1690;223) in incremental costs. A time horizon shorter than 12 months was associated with higher incremental costs (479, 95 % CI: −1024;65); Hill et al. \[[@CR22]\] estimated costs and effects for different time horizons and showed that a longer time horizon led to lower incremental costs. This is likely because of the continuing treatment effect of DES in the subsequent years which would increase in the number of repeat revascularizations avoided compared with BMS. This increase in reduction of repeat revascularization would further offset the cost of the initially more expensive DES.

Meta-regression analyses showed also that the number of repeated revascularizations avoided explained a large proportion of variation (R^2^ = 0.53). As shown in Fig. [2](#Fig2){ref-type="fig"}, there appeared to be a linear association between incremental costs and repeat revascularizations avoided. Incremental QALYs (Fig. [3](#Fig3){ref-type="fig"}), on the other hand, was not associated with incremental costs (R^2^ = 0.001), probably since incremental QALYs are determined by several factors including repeat revascularizations avoided, life-years gained and quality of life values.

Discussion {#Sec11}
==========

This study explored the usefulness of meta-regression analyses in combination with a systematic review of economic evaluations compared with conventional review methods. The aim of conventional systematic reviews is to show relevant publications on the cost-effectiveness of certain treatments in a systematic manner. When possible, conventional reviews describe associations between study characteristics, input parameters and outcomes. However, it is not possible to statistically determine if the association actually exists, which covariates explains the variation best, to correct for interactions or to predict the incremental outcomes. This case study was inspired by meta-analyses of treatment effectiveness studies that are frequently performed to obtain a single summary estimate. More interesting than meta-analyses are meta-regression analyses that try to relate the size of treatment effect to one or more characteristics of the included studies \[[@CR1]\]. Using meta-regression analyses to explore the associations between incremental outcomes and input parameters is unique for a systematic review of economic evaluations and could help to explain variation in cost-effectiveness outcomes between studies. We used meta-regression analyses to explain the variability in the outcomes of cost-effectiveness studies (i.e., incremental costs and effects) of DES versus BMS and found that, besides confirming associations that could be predicted from individual studies, associations at a meta-level also exist, such as an association between outcomes and the quality of the models.

The most important factors that were associated with the results were patient characteristics (age, vessel, lesion), procedure (type of stent and elective versus non-elective), specific input parameters (number of stents per procedure, cost per stent/procedure, restenosis risk with BMS and the efficacy of DES) and the quality of the models. Many of these associations had already been reported in the studies themselves, which can be seen as evidence that the meta-regression produced valid results. However, besides these previously reported associations, we also found associations between study outcomes and the quality of the model, time horizon, efficacy assumptions, and funding which could only be identified at a 'meta level'. Moreover, this review identified an association between the incremental costs and absolute risk reduction in repeat revascularizations on 'meta-level' (Fig. [2](#Fig2){ref-type="fig"}) showing the added value of meta-regression analyses.

Some of the associations we found are desirable since they involve parameters that influence the results and that can be controlled by clinicians and policymakers. For example, factors like the costs of a stent are expected to be associated with the results. Other factors such as patient characteristics can be changed by means of patient selection. However, the presence of other associations such as the quality of the models, assumptions, time horizon or funding raises concerns. Moreover, other parameters were not significantly associated with outcomes (e.g., wait time and incremental costs, or funding and incremental QALYs). These parameters could have influenced the outcomes but are undesirable since e.g., funding should not play a role in the outcomes of the study. It is important for authors to follow the recommendations of the ISPOR-SMDM task force for modelling good research practices \[[@CR27]\] and the recommendations based on the Philips et al. checklist \[[@CR7]\] for modelling studies to increase the quality of the study and generalizability of the results.

Limitations {#Sec12}
-----------

Despite the fact that the quality of the models was assessed by two independent reviewers it was difficult to judge the quality due to subjectivity of the questions; this problem was been recognized in the past \[[@CR28]\]. Furthermore, to provide studies with a score between 0 and 100 % we needed to assume that all questions of the checklist were equally important. Thus studies could obtain a reasonably high score if less informative/important questions were fulfilled. In addition, the quality of the models was based on the documentation of the model and therefore it is possible that studies that scored low did not transparently present model details, however the actual model could be of high quality. Regardless of these limitations, we found a statistically significant association between quality and the outcome repeat revascularization.

Furthermore, title abstract screening was performed by one reviewer which could be seen as a limitation of the study. However, checks of whether the studies included in previously published reviews were also identified with the search, increased the sensitivity of the search and thereby reduced the chance of missing relevant publications. Full assessment and assessing the quality of the model using the Philips checklist was performed by two reviewers independently.

Another limitation of our study is that all 508 analyses were analysed as independent observations even though in reality these 508 analyses were based on 16 studies. We have used study identification number as a random effect in the regression models to address this problem.

In this case study, linear regression models were used to estimate the associations of study characteristics on the outcomes (incremental costs, incremental QALYs and repeat revascularizations avoided) since the number of observations was large. However, regression models could be improved by first considering if the dependent variable (e.g., incremental costs) can best be modelled using a different function (e.g., gamma).

Moreover, meta-regression analyses (bivariate or multivariate) help to explain variation in outcomes, however it also identified associations that were not expected a priori. For example, type of study was associated with the incremental costs, which is not logical since the type of study mainly influences the incremental effects. Covariates that are on beforehand implausible (e.g., type of study and incremental costs) should not be included in future meta-regression analyses since it leads to false positive outcomes.

In addition, transparency in documentation is a major issue leading to a high frequency of missing values that made it impossible to perform multivariate analyses with all of the parameters that were significant in the bivariate analyses. Consequently, we were unable to: 1) take into account interaction effects, 2) determine the most influential covariates, and 3) create a prediction model. A solution could be to include a smaller number of input parameters with only common input parameters (e.g., cost of procedure, time horizon etc.). However, this will lead to fewer associations between outcomes and covariates.

Transparent reporting is crucial in this field and would solve the problem of missing values for systematic reviews such as this. A recently published review on the challenges of modelling the cost-effectiveness of cardiovascular disease interventions has recognized the same problem \[[@CR29]\].

Lastly, we did not include the studies published after January 2012. However, we expect that including newer studies that met inclusion criteria (i.e., estimating the cost-effectiveness of DES versus BMS using modelling methods) do not have an impact on the results of our case study showing that using meta-regression analyses could be useful method in addition to conventional systematic reviews.

To improve this case study lessons can be learned from meta-regression analyses and meta-analyses that are performed for the clinical effectiveness of interventions. More specifically, it could provide guidance in how to handle missing data \[[@CR30]\], how to treat study heterogeneity, how to include covariate interaction \[[@CR31]\]. In addition, it shows limitations of the methods \[[@CR1]\].

Conclusions {#Sec13}
===========

This study has showed that meta-regression analyses can be used to explore relationships between study characteristics and cost-effectiveness outcomes and can draw from the methodology used in other fields even though it is not yet fully developed. Compared with conventional review methods or sensitivity analyses of individual studies meta-regression analyses can be of added value since it identifies significant associations that could not be identified before. The quality of the models was associated with the outcomes of the studies and therefore it is important that a quality check is performed before interpreting the results of the study.

Additional files
================

 {#Sec14}

Additional file 1:**Search string.** (DOCX 15 kb) Additional file 2:**PRISMA guidelines.** (PDF 514 kb)

BMS

:   Bare-metal stents

CEA

:   Cost-effectiveness analysis

DES

:   Drug-eluting stents

ICER

:   Incremental cost-effectiveness ratio

PES

:   Paclitaxel-eluting stent

QALY

:   Quality-adjusted life years

SES

:   Sirolimus-eluting stent

TLR

:   Target lesion revascularization

TVR

:   Target vessel revascularization

ZES

:   Zotarolimus-eluting stent
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